[go: up one dir, main page]

AR022376A1 - Compuestos de 4,4-biarilpiperidina, composicion farmaceutica y uso de los compuestos - Google Patents

Compuestos de 4,4-biarilpiperidina, composicion farmaceutica y uso de los compuestos

Info

Publication number
AR022376A1
AR022376A1 ARP990104494A ARP990104494A AR022376A1 AR 022376 A1 AR022376 A1 AR 022376A1 AR P990104494 A ARP990104494 A AR P990104494A AR P990104494 A ARP990104494 A AR P990104494A AR 022376 A1 AR022376 A1 AR 022376A1
Authority
AR
Argentina
Prior art keywords
compounds
disorders
gastrointestinal
disease
opioid
Prior art date
Application number
ARP990104494A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR022376A1 publication Critical patent/AR022376A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Derivados de 4,4-biarilpiperidina que son potentes y selectivos ligandos para el receptor delta opioide. Los compuestos de formula (1) y sus salesfarmacéuticamente aceptables son ligandos receptores opioides y son utiles, por ejemplo, en el tratamiento de una variedad de desordenes gastrointestinales,inflamatorios y neurologicos. Hay una gran necesidad de compuestos opioides mejorados que estén libres de carácter aditivo y otros efectos adversos de losopiatos convencionales tales como la morfinay la petidina. Se describen compuestos de formula (1) en la que Z1, Z2, R1, R2 y R3 son como se definen en lamemoria descriptiva, a composiciones farmacéuticas que comprenden dichos compuestos y al uso de tales compuestos en la preparacion de medicamentos para tratartrastornos neurologicos, y gastrointestinales. Estos compuestos son utiles en una gran variedad de estados de enfermedad y otras condiciones médicas que puedenser mediadas o beneficiadas a través de la accion de este receptor. Esasenfermedades o condiciones incluyen el tratamiento de rechazo en el transplante deorganos o injertos de piel, epilepsia, dolor cronico, dolor neurogénico, dolor no somático, ataque cardíaco, isquemia cerebral, shock, trauma craneal, traumade espina dorsal, edema pulmonar, edema cerebral, enfermedad de Hodgin, enfermedad de Sjogren, desorden intestinal funcional, síndrome de irritacion deintestinos, diarrea funcional, distension funcional, dispepsia no ulcerogénica y otros desordenes de motilidado secrecion, y émesis, alergias, desordenesrespiratorios, tales como asma, tos y apnea, desordenes inflamatorios tales como artritis reumatoide, osteoartritis, psoriasis y enfermedad inflamatoria delintestino, desordenes de tracto gastrointestinal,urogenital tales como incontinencia urinaria, hipoxia, dano neuronal pipoglicémico, dependencias químicas yadicciones (por ej. a opiatos, benzodiacepinas, cocaina, nicotina o etanol), síntomas de abandono de alcohol o drogas, y déficit cerebral subsecuente acirugías de bypass o injertos.
ARP990104494A 1998-09-09 1999-09-07 Compuestos de 4,4-biarilpiperidina, composicion farmaceutica y uso de los compuestos AR022376A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9956598P 1998-09-09 1998-09-09

Publications (1)

Publication Number Publication Date
AR022376A1 true AR022376A1 (es) 2002-09-04

Family

ID=22275622

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990104494A AR022376A1 (es) 1998-09-09 1999-09-07 Compuestos de 4,4-biarilpiperidina, composicion farmaceutica y uso de los compuestos

Country Status (41)

Country Link
US (2) US6720336B2 (es)
EP (1) EP1112255B1 (es)
JP (1) JP2002524445A (es)
KR (1) KR20010075024A (es)
CN (1) CN1316993A (es)
AP (1) AP2001002088A0 (es)
AR (1) AR022376A1 (es)
AT (1) ATE312819T1 (es)
AU (1) AU749096B2 (es)
BG (1) BG105411A (es)
BR (1) BR9913512A (es)
CA (1) CA2343236C (es)
CO (1) CO5170416A1 (es)
CZ (1) CZ2001850A3 (es)
DE (1) DE69928945T2 (es)
EA (1) EA200100203A1 (es)
EE (1) EE200100145A (es)
ES (1) ES2252960T3 (es)
GE (1) GEP20033025B (es)
GT (1) GT199900146A (es)
HK (1) HK1040396A1 (es)
HN (1) HN1999000149A (es)
HR (1) HRP20010167A2 (es)
HU (1) HUP0103542A3 (es)
ID (1) ID29129A (es)
IL (1) IL141506A0 (es)
IS (1) IS5860A (es)
MA (1) MA26686A1 (es)
NO (1) NO20011183L (es)
NZ (1) NZ509841A (es)
OA (1) OA11648A (es)
PA (1) PA8481301A1 (es)
PE (1) PE20001053A1 (es)
PL (1) PL346648A1 (es)
SK (1) SK3032001A3 (es)
SV (1) SV1999000147A (es)
TN (1) TNSN99169A1 (es)
TR (1) TR200100694T2 (es)
WO (1) WO2000014066A1 (es)
YU (1) YU11501A (es)
ZA (1) ZA200101744B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
EP1038872A1 (en) * 1999-02-22 2000-09-27 Pfizer Products Inc. 4-Phenyl-4-heteroarylpiperdine derivatives as opioid receptor ligands
SE9902765D0 (sv) * 1999-07-21 1999-07-21 Astra Pharma Prod Novel compounds
US6974824B2 (en) * 2001-01-08 2005-12-13 Research Triangle Institute Kappa opioid receptor ligands
EP1279666A1 (en) 2001-07-24 2003-01-29 Pfizer Products Inc. 1-diphenylmethyl-pyrazole derivatives as opioid receptor ligands
ES2311711T3 (es) 2002-02-07 2009-02-16 The Curators Of The University Of Missouri Compuestos de 4-(3-hidroxifenil) o 4-(3-alcoxifenil)-1,2,4-triazol activos como receptores de opioides.
WO2004048334A1 (en) 2002-11-26 2004-06-10 Pfizer Products Inc. Phenyl substituted piperidine compounds for use as ppar activators
SE0203302D0 (sv) * 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0203301D0 (sv) * 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
CN104383542B (zh) * 2003-04-08 2017-09-26 普罗热尼奇制药公司 包含甲基纳曲酮的药物配方
CL2004000754A1 (es) * 2003-04-11 2005-02-25 Janssen Pharmaceutica Nv Uso de compuestos derivados de 4-fenil-4-(1h-imidazol-2-il)piperidina, como agonistas delta-opioides no peptidicos, para preparar un medicamento util en prevenir o tratar trastornos del sistema nervioso central.
US20070078120A1 (en) * 2003-10-21 2007-04-05 Hitoshi Ban Novel piperidine derivative
EP2228369A1 (en) 2003-12-23 2010-09-15 Astex Therapeutics Ltd. Pyrazole derivatives as protein kinase modulators
EP1584335A3 (en) * 2004-04-05 2006-02-22 Laboratorios Del Dr. Esteve, S.A. Active substance combination comprising a carbinol composition and an opioid
US7872023B2 (en) * 2005-02-17 2011-01-18 Research Triangle Institute Kappa opioid receptor ligands
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
AU2006220682B2 (en) * 2005-03-07 2012-05-31 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
WO2006136823A1 (en) * 2005-06-21 2006-12-28 Astex Therapeutics Limited Heterocyclic containing amines as kinase b inhibitors
JP2008546751A (ja) 2005-06-22 2008-12-25 アステックス・セラピューティクス・リミテッド 医薬組成物
WO2006136837A2 (en) 2005-06-23 2006-12-28 Astex Therapeutics Limited Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators
DE102005061427A1 (de) * 2005-12-22 2007-06-28 Grünenthal GmbH Substituierte Oxadiazol-Derivate
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
GB0704932D0 (en) 2007-03-14 2007-04-25 Astex Therapeutics Ltd Pharmaceutical compounds
EP2565195B1 (en) 2007-03-29 2015-05-06 Wyeth LLC Peripheral opioid receptor and antagonists and uses thereof
CA2865661C (en) 2007-03-29 2016-05-17 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
EP2134718A2 (en) * 2007-03-29 2009-12-23 Progenics Pharmaceuticals, Inc. Crystal forms of (r)-n-methylnaltrexone bromide and uses thereof
WO2009099411A1 (en) 2008-02-06 2009-08-13 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
AU2009225434B2 (en) * 2008-03-21 2014-05-22 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
CA2676881C (en) * 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
EP2263664A1 (en) * 2009-05-18 2010-12-22 Nestec S.A. Opioid receptors stimulating compounds (thymoquinone, Nigella sativa) and food allergy
KR102603671B1 (ko) * 2017-01-17 2023-11-17 메비아스 디스커버리 인코포레이티드 치환된 3-디알킬아미노메틸-피페리딘-4-일-벤즈아미드 및 이를 제조 및 사용하는 방법
CN110662541B (zh) * 2017-03-12 2023-02-10 王晓冬 多环胺作为阿片受体调节剂
US11584765B2 (en) 2017-03-12 2023-02-21 Ecstasy LLC Polycyclic amines as sigma receptor modulators
US10172634B1 (en) * 2017-10-16 2019-01-08 Michael Bruce Horowitz Catheter based retrieval device with proximal body having axial freedom of movement
US11548879B1 (en) 2020-07-01 2023-01-10 Ecstasy LLC Polycyclics as sigma receptor modulators

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016280A (en) 1969-07-17 1977-04-05 Byk Gulden Lomberg Chemische Fabrik Gmbh 4,4-Diarylpiperidine compositions and use
DE1936452C3 (de) * 1969-07-17 1975-06-19 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Verfahren zur Herstellung von 4,4-Diphenylpiperidlnen
DE2139085C3 (de) * 1971-08-04 1979-01-18 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Halogenierte 4,4-Diphenyl-piperidine, Verfahren zu deren Herstellung und sie enthaltende Arzneimittel
DE2139084C3 (de) 1971-08-04 1979-03-01 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Verfahren zur Herstellung von 4,4-Diphenyl-piperidinen
DE2166997C3 (de) 1971-08-04 1980-03-27 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Verfahren zur Herstellung von 4,4-Diphenyl-piperidinen
ES2066721B1 (es) * 1993-05-18 1996-02-16 Ferrer Int Nuevos compuestos derivados de la piridina 1,4-disustituida.
US5434171A (en) * 1993-12-08 1995-07-18 Eli Lilly And Company Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates
AU5499396A (en) * 1995-04-05 1996-10-23 Byk Gulden Lomberg Chemische Fabrik Gmbh Use of substituted piperidine or pyrrolidine compounds for t reating sigma-receptor modulated disorders
EP1021185A4 (en) 1996-05-16 2005-09-07 Synaptic Pharma Corp DIHYDROPYRIMIDINES AND THEIR JOBS
JP4403212B2 (ja) 1996-05-31 2010-01-27 エヌピーエス ファーマシューティカルズ インコーポレイテッド 神経障害および神経心理学的障害の治療のための製剤学的薬剤

Also Published As

Publication number Publication date
US20040138220A1 (en) 2004-07-15
IS5860A (is) 2001-02-23
DE69928945D1 (de) 2006-01-19
HUP0103542A3 (en) 2002-11-28
ATE312819T1 (de) 2005-12-15
US20020013321A1 (en) 2002-01-31
AU5383799A (en) 2000-03-27
ID29129A (id) 2001-08-02
ES2252960T3 (es) 2006-05-16
HUP0103542A2 (hu) 2002-01-28
ZA200101744B (en) 2002-06-03
EE200100145A (et) 2002-06-17
EP1112255B1 (en) 2005-12-14
TR200100694T2 (tr) 2001-10-22
HN1999000149A (es) 2000-01-12
NZ509841A (en) 2003-08-29
SK3032001A3 (en) 2002-04-04
KR20010075024A (ko) 2001-08-09
BG105411A (bg) 2001-12-29
TNSN99169A1 (fr) 2005-11-10
YU11501A (sh) 2003-10-31
PL346648A1 (en) 2002-02-25
AU749096B2 (en) 2002-06-20
IL141506A0 (en) 2002-03-10
HRP20010167A2 (en) 2002-02-28
US6720336B2 (en) 2004-04-13
JP2002524445A (ja) 2002-08-06
GEP20033025B (en) 2003-07-25
PA8481301A1 (es) 2000-09-29
EA200100203A1 (ru) 2001-08-27
BR9913512A (pt) 2001-06-05
CZ2001850A3 (cs) 2001-12-12
NO20011183L (no) 2001-05-04
CN1316993A (zh) 2001-10-10
WO2000014066A1 (en) 2000-03-16
MA26686A1 (fr) 2004-12-20
CA2343236C (en) 2006-01-03
HK1040396A1 (zh) 2002-06-07
CO5170416A1 (es) 2002-06-27
OA11648A (en) 2004-12-08
AP2001002088A0 (en) 2001-03-31
NO20011183D0 (no) 2001-03-08
PE20001053A1 (es) 2000-10-14
DE69928945T2 (de) 2006-07-27
CA2343236A1 (en) 2000-03-16
EP1112255A1 (en) 2001-07-04
GT199900146A (es) 2001-02-24
SV1999000147A (es) 2000-09-06

Similar Documents

Publication Publication Date Title
AR022376A1 (es) Compuestos de 4,4-biarilpiperidina, composicion farmaceutica y uso de los compuestos
DE69911259T2 (de) Tricyclische benzodiazepine als vasopressin antagonisten
JPH06501012A (ja) ラパマイシンのカルボン酸エステル
JPS6187623A (ja) ジアゼピン含有医薬組成物
DE69909209T2 (de) Pyrimidinon-derivate, diese verbindungen enthaltenden pharmazeutische zubereitungen und verfharen zu ihrer herstellung
CN102209718A (zh) 氨基甲酸酯化合物或其盐
CN104918921B (zh) 二唑酰胺
DE19624704A1 (de) Neue Pyridylalkansäureamide
WO1997013767A1 (de) Heterocyclisch substituierte 1-indolcarboxamide als cyclooxygenase-2 inhibitoren
DE69633943T2 (de) Morphine derivate mit analgetischen eigenschaften
CN101880286B (zh) 银杏内酯b的水溶性氨基酸酯衍生物
DE69500673T2 (de) Arzneimittel zur therapeutischen und prophylaktischen Behandlung von Krankheiten, die durch Hyperplasie der glatten Muskelzellen bedingt sind
EP0736020B1 (en) 6-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
LV10458B (en) 4,13-dioxabicyclo£8.2.1.|tridecenone derivatives, method and intermediate products for preparation thereof and drugs containing that compounds
AU696447B2 (en) Use of N-cyclohexyl benzamides for treating bowel disorders
EP0386145A1 (de) Thienotricyclen zur behandlung von erkrankungen der bronchien
CN106491593B (zh) 土木香内酯衍生物及其盐在制备治疗炎症性肠病药物中的应用
EP0085893A2 (de) Pyridobenzodiazepinone, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
EP1572685B1 (de) Substituierte benzdioxepine
US5578607A (en) 6-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
CH630895A5 (de) Verfahren zur herstellung neuer oximaetherverbindungen.
DE3133768A1 (de) N-(1-allyl-2-pyrrolidinylmethyl)-2-methoxy-4-amino-5-methylsulfamoylbenzamid, verfahren zu seiner herstellung und es enthaltende pharmazeutisch vertraegliche arzneimittel
US6638546B2 (en) Bioactivity of methyl palmitate obtained from a mangrove plant Salvadora persica L
DE3709699A1 (de) 5-fluoruracil-derivate, verfahren zu ihrer herstellung und ihre verwendung
DE3204169A1 (de) Substituierte thienobenzodiazepinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel

Legal Events

Date Code Title Description
FA Abandonment or withdrawal